ロード中...
The combination of neoantigen quality and T lymphocyte infiltrates identifies glioblastomas with the longest survival
Glioblastoma (GBM) is resistant to multimodality therapeutic approaches. A high burden of tumor-specific mutant peptides (neoantigens) correlates with better survival and response to immunotherapies in selected solid tumors but how neoantigens impact clinical outcome in GBM remains unclear. Here, we...
保存先:
| 出版年: | Commun Biol |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Nature Publishing Group UK
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6478916/ https://ncbi.nlm.nih.gov/pubmed/31044160 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s42003-019-0369-7 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|